The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in langendorff perfused and in isoproterenol-damaged rat hearts

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 273-282

  Pálfi, Anita ^a   Tóth, Ambrus ^a   Kulcsár, Gyozo ^a   Hantó, Katalin ^a   Deres, Péter ^a   Bartha, Éva ^a   Halmosi, Róbert ^a   Szabados, Eszter ^a   Czopf, László ^a   Kálai, Tamás ^a   Hideg, Kálmán ^a   Sümegi, Balázs ^a   Tóth, Kálmán ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 PIPERIDIN 1 YLETHYL)THIO]QUINAZOLIN 4(3H) ONE; 2 [2 (1 PIPERIDINYL)ETHYLTHIO] 4(3H) QUINAZOLINONE; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; HEART INFARCTION; HEART INJURY; HEART MUSCLE INJURY; HEART PROTECTION; MALE; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; RAT;

ANIMALS; ENERGY METABOLISM; ENZYME INHIBITORS; HEART; HYDROGEN PEROXIDE; ISOPROTERENOL; LIPID PEROXIDATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIUM; PERFUSION; PHOSPHORYLATION; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTECTIVE AGENTS; PROTEINS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 25644445311     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.088336     Document Type: Article

References (36)

1. Armstrong SC (2004) Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61:427-436.
2. Becker LB (2004) New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61:461-470.
3. Bergmeyer HU and Bernt E (1974) Lactate dehydrogenase, in Methods of Enzymatic Analysis (Bergmeyer HU ed) 2nd English ed., vol. 2, pp 574-579, Academic Press, London.
4. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, and Sugden PH (1996) Stimulation of the stress-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79:162-173.
5. Bowes J, Ruetten H, Martorana PA, Stockhausen H, and Thiemermann C (1998) Reduction of myocardial reperfusion injury by an inhibitor of poly(ADP-ribose) synthetase in the pig. Eur J Pharmacol 359:143-150.
6. Butterfield DA, Howard BJ, Yatin S, Allen KL, and Carney JM (1997) Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tertbutyl-alpha-phenylnitrone. Proc Natl Acad Sci USA 94:674-678.
7. Chattopadhyay A, Biswas S, Bandyopadhyay D, Sarkar C, and Datta AG (2003) Effect of isoproterenol on lipid peroxidation and antioxidant enzymes of myocardial tissue of mice and protection by quinidine. Mol Cell Biochem 245:43-49.
8. Docherty JC, Kuzio B, Silvester JA, Bowes J, and Thiemermann C (1999) An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Br J Pharmacol 127:1518-1524.
9. Forster G, Bernt E, and Bergmeyer HU (1974) Creatine kinase, in Methods of Enzymatic Analysis (Bergmeyer HU ed), 2nd English ed, vol 2, pp 784-793, Academic Press, London.
10. Grimm D, Elsner D, Schunkert H, Pfeifer M, Griese D, Bruckschlegel G, Muders F, Riegger GA, and Kromer EP (1998) Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res 37:91-100.
11. Ha HC, Hester LD, and Snyder SH (2002) Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci USA 99:3270-3275.
12. Habon T, Szabados E, Kesmarky G, Halmosi R, Past T, Sumegi B, and Toth K (2001) The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovasc Res 52:153-160.
13. Halmosi R, Berente Z, Osz E, Toth K, Literati-Nagy P, and Sumegi B (2001) Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion- induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 59:1497-1505.
14. Hausenloy DJ and Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448-460.
15. Hong F, Kwon SJ, Jhun BS, Kim SS, Ha J, Kim SJ, Sohn NW, Kang C, and Kang I (2001) Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci 68:1095-1105.
16. Kovacs K, Toth A, Deres P, Kalai T, Hideg K, and Sumegi B (2004) Myocardial protection by selective poly(ADP-ribose) polymerase inhibitors. Exp Clin Cardiol 9:17-20.
17. Kulcsar G, Kalai T, Osz E, Sar PC, Jeko J, Sumegi B, and Hideg K (2003) Synthesis and study of new 4-quinazolinone inhibitors of the DNA repair enzyme poly(ADPribose) polymerase (PARP). ARKIVOC 121-131.
18. Lin A (2002) Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 25:17-24.
19. Manikandan P, Sumitra M, Kumar DA, Gayathri C, Arutselvan N, Manohar BM, and Puvanakrishnan R (2002) Antioxidant potential of a novel tetrapeptide derivative in isoproterenol-induced myocardial necrosis in rats. Pharmacology 65:103-109.
20. Martindale JL and Holbrook NJ (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192:1-15.
21. Mizukami Y, Yoshioka K, Morimoto S, and Yoshida K (1997) A novel mechanism of JNK1 activation. Nuclear translocation and activation of JNK1 during ischemia and reperfusion. J Biol Chem 272:16657-16662.
22. Omura T, Yoshiyama M, Shimada T, Shimizu N, Kim S, Iwao H, Takeuchi K, and Yoshikawa J (1999) Activation of mitogen-activated protein kinase in in vivo ischemia/reperfused myocardium in rats. J Mol Cell Cardiol 31:1269-1279.
23. Rakhit RD, Kabir AN, Mockridge JW, Saurin A, and Marber MS (2001) Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury. Biochem Biophys Res Commun 286:995-1002.
24. Serbinova E, Khwaja S, Reznick AZ, and Packer L (1992) Thioctic acid protects against ischemia-reperfusion injury in the isolated perfused Langendorff heart. Free Radic Res Commun 17:49-58.
25. + exchange inhibitor, on cardioprotective effect of ischaemic and angiotensin preconditioning. Mol Cell Biochem 214:31-38.
26. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, and Yoshikawa J (1998) Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38:116-124.
27. Steenbergen C (2002) The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 97:276-285.
28. Szabo G, Liaudet L, Hagl S, and Szabo C (2004) Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 61:471-480.
29. Teerlink JR, Pfeffer JM, and Pfeffer MA (1994) Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 75:105-113.
30. Toth A, Halmosi R, Kovacs K, Deres P, Kalai T, Hideg K, Toth K, and Sumegi B (2003) Akt activation induced by an antioxidant compound during ischemiareperfusion. Free Radic Biol Med 35:1051-1063.
31. Veres B, Radnai B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, and Sumegi B (2004) Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in LLP-induced inflammation in mice. J Pharmacol Exp Ther 310:247-255.
32. Virag L and Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375-429.
33. Yin T, Sandhu G, Wolfgang CD, Burrier A, Webb RL, Rigel DF, Hai T, and Whelan J (1997) Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 272:19943-19950.
34. Zingarelli B, Cuzzocrea S, Zsengeller Z, Salzman AL, and Szabo C (1997) Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 36:205-215.
35. Zingarelli B, Hake PW, O'Connor M, Denenberg A, Kong S, and Aronow BJ (2003) Absence of poly(ADP-ribose) polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol Med 9:143-153.
36. Zingarelli B, Hake PW, O'Connor M, Denenberg A, Wong HR, Kong S, and Aronow BJ (2004) Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am J Physiol 286:H1408-H1415.